By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Immunization are presented in a new report. According to news reporting from Dusseldorf, Germany, by NewsRx journalists, research stated, "To preclinical assess the feasibility of combining oncolytic measles vaccine virus (MeV) with suicide gene therapy for ovarian cancer treatment. We genetically engineered a recombinant MeV armed with a yeast-derived bifunctional suicide gene that encodes for cytosine deaminase and uracil phosphoribosyltransferase (MeV-SCD)."
The news correspondents obtained a quote from the research from the University of Dusseldorf, "From this suicide gene, a chimeric protein is produced that converts the non-toxic prodrug 5-fluorocytosine (5-FC) into highly cytotoxic 5-fluorouracil (5-FU) and directly into 5-fluorouridine monophosphate (5-FUMP) thereby bypassing an important mechanism of chemoresistance to 5-FU. MeV-SCD was demonstrated to infect, replicate in and effectively lyse not only human ovarian cancer cell lines, but also primary tumor cells (albeit at lower efficiencies) that were derived from malignant ascites of ovarian cancer patients. Addition of the prodrug 5-FC significantly enhanced cell killing. Importantly, precision-cut tumor slices of human ovarian cancer patient specimens were efficiently infected with MeV-SCD. The prodrug-converting enzyme SCD was expressed by all infected tumor slices, thereby ensuring provision of the suicide gene arming function in patient-derived materials."
According to the news reporters, the research concluded: "With respect to safety and therapeutic impact, arming of oncolytic measles vaccine virus warrants further clinical investigation for ovarian cancer treatment."
For more information on this research see: Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase. Gynecologic Oncology, 2013;130(2):362-368. Gynecologic Oncology can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Gynecologic Oncology - www.elsevier.com/wps/product/cws_home/622840)
Our news journalists report that additional information may be obtained by contacting A.D. Hartkopf, University of Dusseldorf, Dept. of Obstet & Gynecol, D-40225 Dusseldorf, Germany. Additional authors for this research include S. Bossow, J. Lampe, M. Zimmermann, F.A. Taran, D. Wallwiener, T. Fehm, M. Bitzer and U.M. Lauer (see also Immunization).
Keywords for this news article include: Biotechnology, Europe, Germany, Genetics, Oncology, Proteins, Virology, Carcinoma, Treatment, Dusseldorf, Gynecology, Hydrolases, Proteomics, RNA Viruses, Immunization, Therapeutics, Bioengineering, Ovarian Cancer, Viral Vaccines, Women's Health, Cancer Vaccines, Measles Vaccine, Cytosine Deaminase, Biological Products
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC